Company intelligence / Profile preview

Ikonisys

Ownership: Private
Employees: ~39
Development stage: Commercial

Overview

Ikonisys develops, produces, and markets fully automated digital microscopy platforms—Ikoniscope20® and Ikoniscope20max®—for the early and accurate detection of rare cells. Their solutions are FDA-cleared/CE-marked for several applications including FISH-based cancer diagnostics. The company’s technology automates labor-intensive processes in cytogenetics/oncology labs, improving accuracy, throughput, and consistency. Recent developments include AI-powered features and liquid biopsy tests targeting circulating tumor cells.

Therapeutic areas: OncologyRare Diseases
Modalities: DeviceDiagnostic test (FISH-based)Software application (AI-powered analysis)Liquid biopsy platform
Industry: Pathology

Partnerships

Possible collaboration with Hospitex on cytology sample prep solutions

Beyond the preview

Go deeper on Ikonisys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ikonisys.

Explore the full profile